Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NYSE:CPHI NASDAQ:CWBR NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$0.74+0.1%$1.89$0.61▼$29.40$5.01M1.07837,520 shs456,748 shsCPHIChina Pharma$1.43-2.1%$1.70$1.20▼$3.35$4.67M0.87110,402 shs23,074 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AVIVSVivoSim Labs$1.77-1.7%$1.77$1.41▼$21.96$4.60M0.9456,704 shs3,318 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%+3.53%-10.99%-74.83%-91.08%CPHIChina Pharma0.00%-3.70%-21.47%-35.59%-92.12%CWBRCohBar0.00%0.00%0.00%0.00%-3.53%VIVSVivoSim Labs0.00%+1.43%-4.84%+176,999,900.00%+176,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriacell Therap2.8411 of 5 stars3.55.00.00.02.40.00.6CPHIChina Pharma0.7899 of 5 stars0.05.00.00.01.90.80.0CWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 3.00Buy$32.004,224.32% UpsideCPHIChina Pharma 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AVIVSVivoSim Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/ACPHIChina Pharma$4.30M1.09N/AN/A$0.70 per share2.04CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AVIVSVivoSim Labs$140K32.87N/AN/A$3.67 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)CPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AVIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,396.48%-32.95%-21.31%N/ALatest CWBR, BCTX, VIVS, and CPHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2026VIVSVivoSim LabsN/A-$1.14N/A-$1.14N/A$0.04 million6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41CPHIChina Pharma0.220.790.26CWBRCohBarN/AN/AN/AVIVSVivoSim LabsN/A4.523.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%CPHIChina PharmaN/ACWBRCohBar2.47%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%CPHIChina Pharma17.32%CWBRCohBar6.51%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap86.78 million6.39 millionNo DataCPHIChina Pharma2503.26 million15.92 millionNot OptionableCWBRCohBar102.91 millionN/ANot OptionableVIVSVivoSim Labs202.60 million2.50 millionN/ACWBR, BCTX, VIVS, and CPHI HeadlinesRecent News About These CompaniesVivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14 at 4:59 PM | finanznachrichten.deVivoSim appoints Lialin as Chief Commercial OfficerAugust 14 at 4:59 PM | msn.comVivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing ServicesAugust 14 at 8:24 AM | quiverquant.comQVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14 at 8:24 AM | financialpost.comFVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14 at 8:05 AM | globenewswire.comVivoSim: Fiscal Q1 Earnings SnapshotAugust 12, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, BCTX, VIVS, and CPHI Company DescriptionsBriacell Therap NASDAQ:BCTX$0.74 +0.00 (+0.14%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$0.73 -0.01 (-1.49%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.China Pharma NYSE:CPHI$1.43 -0.03 (-2.05%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$1.40 -0.02 (-1.75%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.CohBar NASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.VivoSim Labs NASDAQ:VIVS$1.77 -0.03 (-1.67%) As of 08/15/2025 03:59 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access